Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain

BACKGROUND: Icatibant is the only subcutaneous treatment for acute Type I and Type II hereditary angioedema with C1-esterase inhibitor deficiency (HAE-C1-INH) licensed for self-administration in Europe. AIM: To compare the economic impact of two icatibant administration strategies: health profession...

Full description

Saved in:
Bibliographic Details
Main Authors: Blasco, Antonio J, Lázaro, Pablo, Caballero, Teresa, Guilarte, Mar
Format: Artigo
Language:Inglês
Published: Springer 2013
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3584739/
https://ncbi.nlm.nih.gov/pubmed/23398817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2191-1991-3-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items